

ASX Announcement



Medibio Limited – 15 February 2022

MEB Announces Extension to Entitlement Offer

Melbourne, Australia and Minneapolis, MN – 15 February 2022: Medibio Limited (“MEB” or “Medibio” or the “Company”) (ASX: MEB)(OTCPINK: MDBIF) provides the following update on the Non-Renounceable Entitlement Offer (“**Entitlement Offer**”).

The Company advises that the Entitlement Offer will be extended by two weeks with a new closing date to 5:00pm (AEDT) 4 March 2022. The revised indicative timetable is set out below.

Event	Date
Entitlement Offer Closing Date	5.00pm Friday, 4 March 2022
Announcement of results of Entitlement Offer	Friday, 11 March 2022
Issue shares and lodge Appendix 2A of Entitlement Offer	Prior to 12.00pm, 11 March 2022
Shares commence trading on a regular basis	Monday, 14 March 2022

**The above timetable is indicative only and subject to change. The quotation of New Shares is subject to ASX approval. Subject to the ASX Listing Rules and Corporations Act and other applicable laws, the Company reserves the right to vary these dates, without notice. Any extension of the Entitlement Offer will have a consequential effect on the issue date of the New Shares.*

How to Accept the Offer

The Company advises that the offer can be taken up on the offer website <https://meb2022entoffer.thereachagency.com/>.

The Entitlement Offer is partially underwritten up to an amount of \$1 million and allows eligible shareholders to subscribe to 1 Offer Share for every 3 Shares held by Eligible Shareholders registered at the Record Date at an issue price of \$0.005 (0.5 cents) per Offer Share with one (1) free Attaching Option for every two (2) Offer Shares at no additional consideration. The Entitlement Offer will raise up to approximately \$3.4 million before costs.

If Shareholders have any questions in relation to applying for the Entitlement Offer, they can contact the Company’s Share Registry, Computershare on 1300 855 080 (within Australia) or +61 3 9415 4000 (outside Australia) Monday to Friday 8:30am – 5:00pm AEDT.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

About Medibio Limited Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.